bioRxiv Science⌕ Search

Biology subjects

Nerella, S.

Publications and source records attributed to Nerella, S..

2 recordsLinked to original sources

Allergen-responsive T helper type 2 cells revealed by high-dimensional profiling in allergen challenged human airways

Asthma is a chronic inflammatory disease affecting over 300 million people worldwide. This disease has multiple underlying etiologies, and a major endotype of asthma is characterized by cellular and molecular signatures of type 2 (allergic) inflammation. In this study we conducted bronchoscopies with airway segmental allergen challenge in allergic asthmatics to dissect airway responses to allergen. Using mass cytometry and single-cell RNA sequencing, we characterized with high resolution the airway immune landscape before and after allergen challenge and the heterogeneity present between subjects. This heterogeneity generally falls along a type 1/ type 2 axis. In type 2 high individuals, we identified allergen-reactive Th2 cells by using TCR sequences to barcode clonal T cell populations in single-cell genomic and activation-induced marker expression assays. These potentially pathogenic Th2 cell clones were present systemically and expanded following allergen challenge, connecting local lung inflammation to systemic clonal Th2 cell dynamics. Th2 cell airway ingress was coordinated with myeloid cell expression of T cell chemoattractants including CCL17 and CCL22. This study provides insight into the molecular and cellular components of allergen-induced tissue inflammation in asthma. Deeper resolution of the T cell response to aeroallergens may inform novel diagnostic and therapeutic strategies for asthma and other allergic airway diseases.

immunology↗

HuR Regulates GATA3-Driven Type 2 Inflammation in CD4⁺ T cells and ILC2 in Airway Inflammation

Type 2-high asthma is driven by coordinated GATA3-dependent programs in CD4 T cells and group 2 innate lymphoid cells (ILC2). Although biologics targeting Th2 cytokines benefit subsets of patients, many remain symptomatic, suggesting upstream regulatory mechanisms may sustain type 2 inflammation. We investigated whether the RNA-binding protein HuR (ELAVL1) functions as a post-transcriptional regulator of GATA3-driven type 2 inflammation in allergic asthma. Using a house dust mite (HDM) model in vivo, HuR inhibition with KH-3 reduced lung inflammation, suppressed Th2 cytokine expression, accelerated Gata3 mRNA decay in lung CD4 T cells, and attenuated airway hyperresponsiveness toward control levels. In ex vivo-activated human lung CD4 T cells, KH-3 accelerated GATA3 mRNA decay with minimal effects on RORC or TBX21 and selectively reduced Th2 cytokine secretion, while IL-10 and IL-2 were unchanged. Similarly, ILC2s isolated from PBMCs of type 2-high asthmatic donors showed reduced GATA3 mRNA stability and diminished Th2 cytokine production following KH-3 treatment. Single-cell transcriptomic analysis of bronchoalveolar lavage fluid after allergen challenge in asthmatic subjects demonstrated co-enrichment of ELAVL1 and GATA3 within Th2 clusters in human airways. Together, these findings identify HuR as a therapeutically targetable upstream regulator of GATA3-driven type 2 inflammation in allergic asthma.

immunology↗